Outcome after left ventricular assist device exchange.

Autor:	Niamat J; Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands., Ramjankhan F; Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands., Van Der Kaaij N; Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands., Gianoli M; Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands., Van Laake LW; Department of Cardiology, University Medical Center Utrecht, Utrecht, Netherlands., Mokhles MM; Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
Jazyk:	angličtina
Zdroj:	European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery [Eur J Cardiothorac Surg] 2024 Oct 01; Vol. 66 (4).
DOI:	10.1093/ejcts/ezae317
Abstrakt:	Objectives: Left ventricular assist device (LVAD) therapy has evolved from a short-term bridge-to-transplant strategy into a long-term and often chronic therapy due to long waiting times for heart transplantation and application as destination therapy. Consequently, patients are at risk of developing complications necessitating LVAD exchange. The aim of this study is to assess patient outcomes after LVAD exchange. Methods: Patients who underwent LVAD exchange between January 2010 and December 2022 were included. Logistic and cox regression analyses were used to identify potential risk factors for short and long-term adverse events, respectively. Survival after exchange was assessed using Kaplan-Meier estimates. Results: Sixty-one patients underwent a total of 80 LVAD exchanges. Most frequently observed short-term complications were pulmonary infections (16.3%) and right heart failure (16.3%). Exit-site infections (34.7%) and device malfunctions (25.3%) were the most often observed long-term complications. HeartWare ventricular assist device as index device was associated with a higher risk of right heart failure [hazard ratio 6.42, 95% confidence interval (CI) 1.80-22.90] and respiratory failure (hazard ratio 7.81, 95% CI 1.95-31.23) compared to HeartMate II and HeartMate 3. Survival was 83% (95% CI 75.5-95.3%) at 1 year and 67% (95% CI 53.9-84.7%) at 6 years after exchange. After 5 years, 25.0% was transplanted, 23.8% had undergone a re-exchange and 32.5% was alive without new intervention. Conclusions: Although LVAD exchange can be performed with a relatively low mortality, other post-operative adverse events are common. Patients with the HeartWare ventricular assist device as index device may be at higher risk of developing right heart failure and respiratory failure after exchange. (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu